349 related articles for article (PubMed ID: 30700265)
1. The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
Darlix A; Hirtz C; Thezenas S; Maceski A; Gabelle A; Lopez-Crapez E; De Forges H; Firmin N; Guiu S; Jacot W; Lehmann S
BMC Cancer; 2019 Jan; 19(1):110. PubMed ID: 30700265
[TBL] [Abstract][Full Text] [Related]
2. Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer.
Darlix A; Hirtz C; Mollevi C; Ginestet N; Tiers L; Jacot W; Lehmann S
Int J Cancer; 2021 Oct; 149(8):1605-1618. PubMed ID: 34196964
[TBL] [Abstract][Full Text] [Related]
3. Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thezenas S; Jacot W
BMC Cancer; 2016 Jul; 16():428. PubMed ID: 27387327
[TBL] [Abstract][Full Text] [Related]
4. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?
Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thézenas S; Jacot W
Int J Cancer; 2016 Nov; 139(10):2299-311. PubMed ID: 27464303
[TBL] [Abstract][Full Text] [Related]
5. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.
Matsuo S; Watanabe J; Mitsuya K; Hayashi N; Nakasu Y; Hayashi M
Breast Cancer Res Treat; 2017 Feb; 162(1):169-179. PubMed ID: 28084583
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
[TBL] [Abstract][Full Text] [Related]
9. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
10. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
[TBL] [Abstract][Full Text] [Related]
11. Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma.
Claude L; Perol D; Ray-Coquard I; Petit T; Blay JY; Carrie C; Bachelot T
Radiother Oncol; 2005 Sep; 76(3):334-9. PubMed ID: 16024123
[TBL] [Abstract][Full Text] [Related]
12. External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.
Genre L; Roché H; Varela L; Kanoun D; Ouali M; Filleron T; Dalenc F
Eur J Cancer; 2017 Feb; 72():200-209. PubMed ID: 28042991
[TBL] [Abstract][Full Text] [Related]
13. External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience.
Griguolo G; Jacot W; Kantelhardt E; Dieci MV; Bourgier C; Thomssen C; Bailleux C; Miglietta F; Braccini AL; Conte P; Ferrero JM; Guarneri V; Darlix A
Breast; 2018 Feb; 37():36-41. PubMed ID: 29073498
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
15. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors.
Berghoff AS; Bago-Horvath Z; Ilhan-Mutlu A; Magerle M; Dieckmann K; Marosi C; Birner P; Widhalm G; Steger GG; Zielinski CC; Bartsch R; Preusser M
Br J Cancer; 2012 Oct; 107(9):1454-8. PubMed ID: 23047551
[TBL] [Abstract][Full Text] [Related]
16. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
18. Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
Jin J; Gao Y; Zhang J; Wang L; Wang B; Cao J; Shao Z; Wang Z
BMC Cancer; 2018 Apr; 18(1):446. PubMed ID: 29673325
[TBL] [Abstract][Full Text] [Related]
19. Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer.
Wu Q; Sun MS; Liu YH; Ye JM; Xu L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12333-12353. PubMed ID: 37432458
[TBL] [Abstract][Full Text] [Related]
20. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
